540359 PARMAX

Parmax Pharma Share Price

₹42.71 -1.51 (-3.41%)

03 Jan, 2025 00:01

SIP TrendupStart SIP in PARMAX

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -14.15%
  • Over 3 Month -3.59%
  • Over 6 Month + 44.14%
  • Over 1 Year + 31.58%
SIP Lightning

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹42.71
-1.51 (-3.41%)
pointer
  • stock-down_img
  • Bullish Moving Average 4
  • stock-up_img
  • Bearish Moving Average 12
  • 20 Day
  • ₹44.39
  • 50 Day
  • ₹44.72
  • 100 Day
  • ₹42.75
  • 200 Day
  • ₹39.40

Resistance and Support

44.15 Pivot Speed
  • R3 50.40
  • R2 48.41
  • R1 46.14
  • S1 41.88
  • S2 39.89
  • S3 37.62

What's your outlook on Parmax Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 22.68 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -51% needs improvement, ROE of -8146% is poor and needs improvement. The company has a high debt to equity of 8326%, which can be a reason to worry. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
62.9%
6.3%

About Parmax Pharma

  • NSE Symbol
  • PARMAX
  • BSE Symbol
  • 540359
  • Managing Director
  • Dr. Umang Alkesh Gosalia
  • ISIN
  • INE240T01014

Similar Stocks to Parmax Pharma

Parmax Pharma FAQs

Parmax Pharma share price is ₹42 As on 02 January, 2025 | 23:47

The Market Cap of Parmax Pharma is ₹16 Cr As on 02 January, 2025 | 23:47

The P/E ratio of Parmax Pharma is -4.7 As on 02 January, 2025 | 23:47

The PB ratio of Parmax Pharma is 197 As on 02 January, 2025 | 23:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23